B-cell depletion1‡
|
B-cell repletion1‡
Data from the two RMS Phase 3 studies indicate a median time to B-cell recovery to either LLN or baseline value of 24.6 weeks post-treatment discontinuation.
PK and PD (B-cell) modelling and simulation for B-cell repletion corroborate these data, predicting median time to B-cell recovery to LLN of 23 weeks post-treatment discontinuation.
Mechanism of Action
KESIMPTA® binds specifically to the small and large extracellular loops of the CD20+ molecule1✝︎
KESIMPTA® is a selective immunomodulator1✝︎
Ofatumumab is the first and only recombinant fully human monoclonal immunoglobulin G1 (IgG1) antibody against human CD20 expressed on B-cells.1,2* |
After subcutaneous administration, ofatumumab is believed to be predominantly absorbed via the lymphatic system similarly to other therapeutic monoclonal antibodies.
KESIMPTA® binds specifically to a distinct epitope encompassing both the small and large extracellular loops of the CD20 molecule.1
Binding induces lysis of CD20+ B-cells, primarily through complement-dependent cytotoxicity (CDC) and to a lesser extent through antibody-dependent cell-mediated toxicity (ADCC).1
KESIMPTA® has also been shown to induce cell lysis in both high and low CD20-expressing cells. CD20-expressing T cells are also depleted by KESIMPTA®.1
Images adapted from the KESIMPTA® Product Monograph.
* Comparative clinical significance has not been established.
† Clinical significance has not been established.
‡ Pooled data from treatment epochs of ASCLEPIOS I and II (safety set).
References
KESIMPTA® Product Monograph. Novartis.
Data on file. Novartis Pharmaceuticals Canada Inc.
KESIMPTA, SensoReady and the Go Program are registered trademarks.
© Novartis Pharmaceuticals Canada Inc. September 2025
FA-11447944E
Related content
KESIMPTA® Efficacy Profile
KESIMPTA® Efficacy Profile
Learn more about KESIMPTA®’s efficacy profile and clinical trials.
Dosing & Administration
Dosing & Administration
Learn more about how to initiate, dose, and administer KESIMPTA®.